Polomar Health Services (PMHS) Gross Margin (2022 - 2026)
Polomar Health Services (PMHS) posted Gross Margin of 61.22% for Q2 2026, up 11.83% on a QoQ basis from 54.75% in Q1 2026, and down 883.0% year-over-year from 7.82% in Q2 2025.
Powered by 
Analysis
Polomar Health Services (PMHS) Gross Margin (2022 - 2026) Analysis & Trends
Polomar Health Services has reported Gross Margin for 5 years, with the latest figure at 61.22% in Q2 2026.
- On a quarterly basis, Gross Margin fell 883.0% year-over-year to 61.22% in Q2 2026; TTM through Jun 2026 was 61.14%, a 12.0% decrease from a year earlier, with the FY2025 full-year figure at 70.98%, up 1844.0% from the prior year.
- Gross Margin was 61.22% for Q2 2026 at Polomar Health Services, up from 54.75% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q3 2022, with the low at 19.93% in Q1 2024.
- Average Gross Margin over 5 years is 71.53%, with a median of 70.45% recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Gross Margin sank 4368 bps in 2024, then soared 5012 bps in 2025.
- Over 5 years, Gross Margin stood at 100.0% in 2022, then decreased by 13 bps to 87.14% in 2023, then tumbled by 50 bps to 43.46% in 2024, then soared by 63 bps to 71.0% in 2025, then decreased by 14 bps to 61.22% in 2026.
- The last three Gross Margin figures came in at 61.22% (Q2 2026), 54.75% (Q1 2026), and 71.0% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.62 Bn | 38.96 Bn | 2.15 Bn | 51.98% |
| 2 | Viatris | 18.96 Bn | 18.08 Bn | 1.46 Bn | 38.77% |
| 3 | Dr Reddys Laboratories | 9.79 Bn | 9.61 Bn | 396.53 Mn | 46.52% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | 42.01% |
| 5 | Bausch Health Companies | 2.29 Bn | 453.25 Mn | 2.10 Bn | 73.60% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 4.68% |
| 7 | Ani Pharmaceuticals | 1.50 Bn | 1.14 Bn | 165.89 Mn | 62.35% |
| 8 | Amphastar Pharmaceuticals | 1.01 Bn | 719.36 Mn | 93.47 Mn | 50.83% |
| 9 | Fennec Pharmaceuticals | 401.07 Mn | 359.82 Mn | 17.15 Mn | 95.97% |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | 61.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.22% |
| Mar 31, 2026 | 54.75% |
| Dec 31, 2025 | 71.00% |
| Sep 30, 2025 | 70.14% |
| Jun 30, 2025 | 70.05% |
| Mar 31, 2025 | 70.06% |
| Dec 31, 2024 | 43.46% |
| Sep 30, 2024 | 90.00% |
| Jun 30, 2024 | 70.76% |
| Mar 31, 2024 | 19.93% |
| Dec 31, 2023 | 87.14% |
| Sep 30, 2023 | 92.85% |
| Dec 31, 2022 | 100.00% |
| Sep 30, 2022 | 100.00% |